IMMUVANCE

Welcome to the Brand page for “IMMUVANCE”, which is offered here for Therapeutic preparations, antibodies for use in targeting the ccr5 cell receptor; therapeutic preparations for the treatment of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, covid-19; therapeutic preparations for the prevention of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, covid-19;providing a website featuring medical information; providing a website featuring information in the field of antibodies for use in targeting the ccr5 cell receptor; providing health and medical information, providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, covid-19; all of the forgoing excluding information directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting;scientific research consulting services in the field of immunology; scientific research consulting services in the field of antibodies for use in targeting the ccr5 cell receptor; scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, covid-19; medical research services; medical research services in the field of antibodies for use in targeting the ccr5 cell receptor; medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of hiv, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, covid-19; all of the foregoing excluding medical research and scientific research consulting services directed to adjuvants for vaccines and molecular genetics and genomics testing and reporting;.

Its status is currently believed to be active. Its class is unavailable. “IMMUVANCE” is believed to be currently owned by “CytoDyn Inc.”